• Home
• Register
• Presentations
• Faculty
• Contact Us
• Email Colleague
• Aging Male 2004 Presentations

Biographical sketch:

Dr. T. Hugh Jones is a consultant physician in general internal medicine, diabetes and endocrinology, at Barnsley District General Hospital, Barnsley and honorary senior clinical lecturer, Hormone and Vascular Biology Research Group, Academic Unit of Endocrinology, Division of Genomic Medicine, University of Sheffield Medical School, United Kingdom.

Curriculum vitae:

Qualifications:

• 1975 BSc with Honours in Biochemistry, University of Sheffield.
• 1980 MB ChB, University of Sheffield.
• 1984 MRCP (UK)
• 1990 MD University of Sheffield
• Studies on the Hypothalamic and Paracrine Control of Anterior Pituitary Hormone Secretion.
• 2001 FRCP (London)

Accreditation:

• General Medicine, Endocrinology and Diabetes Mellitus (1993)

Administrative appointments:

• Programme Director for Training of Specialist Registrars in Diabetes, Endocrinology and General Internal Medicine to the North Trent Rotational Training Scheme.

Previous appointments:

• Aug. 1980 - Jan. 1981 House Officer in General Medicine, Royal Hallamshire and Lodge Moor Hospitals, Sheffield.
• Feb 1981 - Jul 1981 House Officer in General Surgery (University Department of Surgery) Northern General Hospital, Sheffield.
• Aug. 1981 - Mar 1983 Senior House Officer in General Medicine, Diabetes and Endocrinology. Barnsley District General Hospital.
• Mar 1983 - Mar 1985 Medical Registrar (Rotating). Royal Hallamshire Hospital, Sheffield Neurology, General Medicine with Cardiothoracic Disorders, General Medicine, Endocrinology and Diabetes.
• Mar 1985 – Dec 1987 Research Fellow, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School.
• May 1987 - Jul 1987 Medical Registrar in General Medicine, Cardiovascular disease and Hypertension (University Department of Therapeutics).
• Jan 1988 - Jan 1994 Lecturer and Honorary Senior Registrar in Medicine, Diabetes and Endocrinology, Northern General and Royal Hallamshire Hospitals, Sheffield.
• Feb 1994 - April 1997 Consultant Physician in General Medicine and Endocrinology at the Royal Hallamshire Hospital, Sheffield.
• May 1997 - July 1997 Senior Clinical Research Fellow, Metabolic Bone Unit, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield.
• Aug 1997 - Jan 1998 Consultant Physician in General Medicine, Diabetes and Endocrinology, Rotherham District General Hospital, Rotherham.

Membership of learned societies:

• Royal College of Physicians of London
• Society for Endocrinology
• Endocrine Society of America
• The International Pituitary Pathologists Club
•  ISSAM (International society for the study of the aging Male)

Publications:

Book Chapter

•  Jones TH, Jones RD, Channer KS. (2003) Testosterone and its beneficial actions on cardiovascular disorders. In: Recent Research Developments in Endocrinology & Metabolism Volume 1, Chapter 11, p143- 168 (book chapter)

Reviews

• T H Jones, B L Brown, P R M Dobson (1990) Paracrine control of anterior pituitary hormone secretion. Journal of Endocrinology. 127, 5 -13
• R L Kennedy, T H Jones (1991) Cytokines and endocrinology: In health and disease. Journal of Endocrinology. 129, 167 -178
• R L Kennedy, T H Jones, H S Cuckle (1992) Down's syndrome and the thyroid. Clinical Endocrinology. 37, 471 - 476
• T H Jones, C D Figueroa, K D Bhoola (1992) Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours. Acta Endocrinologica. 127, 481 – 484
• T H Jones, R L Kennedy (1993) Cytokines and hypothalamic-pituitary function. Cytokine. 5, 531 - 538
• T H Jones (1994) Interleukin-6 an 'endocrine cytokine'. Clinical Endocrinology. 40, 703 - 713.
• T H Jones (1995) The management of hyperprolactinaemia. British Journal of Hospital Medicine 53, 374 - 378
• KM English, Steeds R, Jones TH, Channer KS (1997) Testosterone and coronary heart disease: Is there a link? Quarterly Journal of Medicine 90, 787-791.
• T H Jones, K Hupart, S Wadler (1998) Side effects of alfa interferon : Endocrine mediated mechanisms of fatigue. Seminars in Oncology 25 (Suppl 1), 54-63
• Pugh PJ, English KM, Jones TH, Channer KS. Testosterone: a natural tonic for the failing heart? Quarterly Journal of Medicine 2000, 93; 689-694.
• Pugh PJ, Jones RD, Jones TH Channer KS. (2002) Heart failure as an inflammatory condition: potential role for androgens as immune modulators. European Journal of Heart failure 4, 673-680.
• Channer KS, Jones TH. (2003) Cardiovascular effects of testosterone: implications of the ‘male menopause’? Heart 89 , 121-122
• Jones RD, Pugh PJ, Jones TH, Channer KS (2003) The vasodilatory action of testosterone: a potassium-channel opening or calcium antagonistic action? British Journal of Pharmacology 138, 733-744.
• Malkin CJ, Pugh PJ, Jones TH, Channer KS (2003) Testosterone for secondary prevention in men with ischaemic heart disease? Quarterly Journal of Medicine 96, 521-529.
• Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS (2003) Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. Journal of Endocrinology 178, 373-380.
• Jones TH, Jones RD, Channer KS (2004) Testosterone and Cardiovascular Disorders. Recent Research Developments in Endocrinology and Metabolism (In press)
• Nieschlag E, Behre HM, Bouchard P, Corrales J, Jones TH, Stalla G, Webb S, Wu F. (2004) Testosterone replacement therapy: current trends and future directions. Human Reproduction Update 10, 409-419.
• Kapoor D, Jones T.H. (2005) Smoking and Hormones in health and endocrine disorders. European Journal of Endocrinology 152, 491-499
• Jones RD, Nettleship JE, Jones TH, Channer KS. (2005) Testosterone and atherosclerosis in aging men: Purported association and clinical Implications. American Journal of Cardiovascular Drugs 5,141-15
• Kapoor D, Malkin C J, Channer KS, Jones T H (2005) Androgens, insulin resistance and vascular disease in men. Clinical Endocrinology 63, 329-250.

Original papers

• C A Austin, P A Cann, T H Jones, C D Holdsworth (1984) Exacerbation of diarrhoea and pain in patients treated with 5-amino-salicyclic acid for ulcerative colitis. Lancet 1 (8382), 917 - 18
• A J P Yates, T H Jones, K I Mundy, R V Hague, C B Brown, D Guilland-Cummings, J A Kanis (1984) Immobilisation hypercalcaemia in adults and treatment with Clodronate. British Medical Journal. 289, 1111 - 1112
• T H Jones, B L Brown, P R M Dobson (1988) Evidence that Angiotensin II is a paracrine agent mediating gonadotrophin-releasing hormone stimulated inositol phosphate production and prolactin secretion in the rat. Journal of Endocrinology. 116, 367 - 371
• T H Jones, B L Brown, P R M Dobson (1989) Bradykinin stimulates phosphoinositide metabolism and prolactin secretion in rat anterior pituitary cells. Journal of Molecular Endocrinology. 2, 47 - 53
• T H Jones, C D Figueroa, C M Smith, D R Cullen, K D Bhoola (1990) Characterisation of a tissue kallikrein in human prolactin secreting adenomas. Journal of Endocrinology. 124, 327 - 331
• T H Jones, V Bergvall, J P P Bradshaw (1990) Carotid artery stenosis and thrombosis due to cavernous sinus thrombosis in fusobacterium necrophorum meningitis Postgraduate Medical Journal. 55, 747 - 750
• T H Jones, B L Brown, P R M Dobson (1990) Kallidin-induced stimulation of inositol phosphate production and prolactin release in rat anterior pituitary cells. Acta Endocrinologica (Copenh.) 123, 37 - 42.
• T H Jones, S Justice, A Price, K Chapman (1991) Interleukin-6 secreting human pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism. 73, 207 - 209.
• T H Jones (1991) Sodium Valproate-induced menstrual disturbance in young women. Hormone Research. 35, 82 - 85
• S Rahman, R A D Bunning, P R M Dobson, D B Evans, K Chapman, T H Jones, B L Brown, R G G Russell (1992)
• Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochemica et Biophysica Acta. 1135, 97 - 102
• R L Kennedy, T H Jones, R Davies, S K Justice, N R Lemoine (1992) Release of interleukin-6 by human thyroid epithelial cells immortalised by simian virus 40 DNA transfection. Journal of Endocrinology. 133, 447 - 482
• T H Jones, C D Figueroa, C M Smith, D R Cullen, K D Bhoola (1992). Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas. Journal of Endocrinology. 134, 149 -154.
• T H Jones, C D Figueroa, C M L Smith, D R Cullen, D K Bhoola (1992) Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas. Recent Progress in Kinins, Agents and Actions. 38, (Suppl.) 175 -182.
• T H Jones, B L Brown, D R Cullen, P R M Dobson (1992). Effect of the GABA agonist muscimol on prolactin secretion from human prolactin-secreting adenomas and GH3 rat pituitary tumour cells. Hormone Research. 37, 113 - 118.
• T H Jones, J F Darne (1993) Self-administered subcutaneous human menopausal gonadotrophin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotrophic hypogonadism. Clinical Endocrinology. 38, 203-208.
• T H Jones, R L Kennedy, S K Justice, A Price (1993) Interleukin-1 stimulates the release of interleukin-6 from cultured human pituitary adenoma cells. Acta Endocrinologica. 128, 405 - 410
• T H Jones, R L Kennedy, S K Justice, A Price (1993) Pituitary adenomas with high and low basal inositol phospholipid turnover, the stimulatory effect of kinins and an association with interleukin-6 secretion. Clinical Endocrinology, 39, 433 - 439.
• T H Jones, M Daniels, R A James, S K Justice, R McCorkle, A Price, P Kendall-Taylor, A P Weetman (1994) Production of bioactive and immunoreactive IL-6 and expression of IL-6 mRNA by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 78, 180 -189.
• T H Jones, R B Fraser (1994) Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. British Journal of Obstetrics & Gynaecology. 101, 349 - 350.
• T H Jones, S M Hunter, A Price, G D Angelini (1994) Should thyroid function be assessed before cardiopulmonary bypass surgery? Annals of Thoracic Surgery. 58, 434 - 436
• T H Jones, J F Darne, H McGarrigle (1994) Diurnal rhythm of testosterone induced by twice weekly HCG therapy in isolated hypogonadotrophic hypogonadism: A comparison between subcutaneous and intramuscular HCG administration. European Journal of Endocrinology 131, 173 - 178.
• T H Jones, S M Hunter, A Price, G D Angelini (1995) Effect of cardiopulmonary bypass on thyroid function. Annals of Thoracic Surgery 59, 1273 - 1275.
• C-Y Guo, T H Jones, R Eastell (1997) Effect of treatment of isolated hypogonadotrophic hypogonadism on bone mineral density and bone turnover. Journal of Clinical Endocrinology and Metabolism 82, 658-665.
• T H Jones, R L Kennedy, S K Justice, R Davies (1997) Effects of glucocorticoids and oestrogen on IL-6 production by human thyrocytes from patients with Graves disease and toxic multinodular goitre and from HT ori 3 cells. European Journal of Endocrinology 137, 429-432.
• T H Jones, S K Justice, A Price (1997) Suppression of Tyrosine Kinase activity inhibits [3H] thymidine uptake by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 82 , 2143-2147.
• T H Jones, S K Justice, W R Timperley, J A Royds (1997) Effects of IL-1 and dexamethasone on IL-6 production and growth in meningiomas. Journal of Pathology 183, 460-468.
• European Metrodin HP Study Group (1998) Efficacy and safety of highly purified urinary follicle stimulating hormone with human chorionic gonadotropin for treatment of azospermia in men with isolated hypogonadotrophic hypogonadism. Fertility and Sterility 70, 256-262.
  MER Suliman, JA Royds, JA Baxter, WR Timperley, DR Cullen, TH Jones (1999) IL-8 mRNA expression by in-situ hybridisation in human piuitary adenomas. European Journal of Endocrinology 140, 155-158.
• VM Bryant, A Wilson, TH Jones, RV Hague (1999) A high uptake eye and foot screening service for an urban population. Diabetic Medicine 16, 609-613.
• AA Adeniji, FM Fairlie, TH Jones, P Wilkinson (1999) Pregnancy and blue rubber bleb naevus syndrome. British Journal of Obstetrics and Gynaecology In Press.
• KM English, O Mandour, RP Steeds, MJ Diver, THJones, KS Channer (2000) Men with coronary heart disease have lower levels of androgens than those with normal coronary angiograms. European Heart Journal 21, 890-894.
• KM English, RD Jones, TH Jones, AH Morice, KS Channer (2000) Aging reduces the responsiveness of coronary arteries from male Wister rats to the vasodilatory action of testosterone. Clinical Science 99, 77-82.
• English KM. Steeds RP, Diver MJ, Jones TH, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomised, double-blind, placebo-controlled study. Circulation 2000, 102; 1906-1911.
• English KM, Pugh PJ, Parry H, Scutt NE, Channer KS, Jones TH. The effect of cigarette smoking on the level of bioavailable testosterone in healthy men. Clinical Science 2001; 100: 661-665.
• Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH. Mdm2 and the p53 pathway in human pituitary adenomas. Clinical Endocrinology 2001; 54: 317-325.
• Korbonits M, Chitnis MM, Gueorguiev, Norman D, Rosenfelder N, Suliman M, Jones TH, Noonan K, Fabbri A, Besser GM, Burrin JM, Grossman AB. The release of leptin and its effect on hormone release from pituitary adenomas. Clinical Endocrinology 2001; 54: 781-789.
• English KM, Jones RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Hormone and Metabolic Research 2001; 33: 645-652.
• Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer, KS. The Pulmonary Vasodilatatory Action of Testosterone – Evidence of a Calcium Antagonistic Action. Journal of Cardiovascular Pharmacology 2002; 39: 814-823.
• English KM, Jones RD, Jones TH, Morice AH, Channer KS. Testosterone Acts as a Coronary Vasodilator by a Calcium Antagonistic Action. Journal of Endocrinological Investigation 2002; 25: 455-458.
• Pugh PJ, Channer KS, Parry H, Downes T, Jones TH. (2002) Bioavailable testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocrine Research 28, 161-173.
• Pugh PJ, Jones RD, Jones TH, Channer KS. (2002) Intrinsic responses of rat coronary arteries in vitro – Influence of testosterone, calcium, and effective transmural pressure. Endocrine 19, 155-161.
• Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH. (2003) Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. European Journal of Endocrinology 148, 111-120.
• Pugh PJ, Jones TH, Channer KS. (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal 24, 909-915.
• Jones RD, Ruban LN, Morton IE, Roberts SA, English KM, Channer KS, Jones TH. (2003) Testosterone inhibits the prostaglandin F2a -mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: Evidence of an antagonistic action upon store operated calcium channels. Journal of Endocrinology 178, 381-393.
• Borg SA, Kerry KE, Baxter L, Royds JA, Jones TH. (2003) Expression of Interleukin-6 and its effects on growth of HP75 human pituitary tumour cells. Journal of Clinical Endocrinology and Metabolism 88, 4938-4944.
• Ross RJM, Jabbar A, Jones TH, Roberts B, Dunkley K, Hall J, Long A, Levine H, Cullen DR. (2004) Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. European Journal of Endocrinology 150, 57-63.
• Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and mood. Heart (In press).
• Jones RD, English KM, Jones TH, Channer KS (2004) Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct genomic action. Clinical Science 107; 149-158.
• Scragg JL, Jones RD, Channer KS, Jones TH, Peers C. (2004) Testosterone is a potent inhibitor of L-type Ca2+ channels.
  Biochemical and Biophysical Research Communications 318, 503-506.
• Jones R.D. English K.M. Jones T.H. Channer K.S. (2004) Testosterone induced coronary vasodilation occurs via a non-genomic mechanism : Evidence of a direct calcium antagonistic action. Clinical Science 107, 149-158.
• Malkin CJ, Pugh PJ, Kapoor D, Jones RD, Channer KS, Jones TH (2004) The effects of testosterone replacement on endogenous cytokines and lipid profiles in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 89, 3313-3318.
• Malkin CJ, Morris PD, Channer KS, Jones TH (2004) A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. European Journal of Endocrinology 151, 241-249.
• Jones RD, Jones TH, Channer KS (2004) Replacement therapy, not recreational tonic. Nature. 4321; 439.
• Borg SA, Royds JA, Battersby RD, Jones TH (2005) Correlation of VEGF production with IL1a and IL6 secretion by human pituitary adenoma cells. European Journal of Endocrinology. 152; 293-300
• Smith A, Jones RD, English KM, Channer KS, Jones TH (2005) Testosterone does not adversely effect the coagulation status in men with chronic stable angina. European Journal of Endocrinology. 152; 285-291
• Kapoor D, Ng JP, Jones TH (2005) Falsely high glycated hemoglobin (HbA1C) due to Hemoglobin Osu-Christiansborg. Clinical and Laboratory Haematology 27; 334-335.
• Malkin CJ, Pugh PJ, West J, van Beek EJ, Jones TH, Channer KS (2005) Testosterone therapy in men with moderate severity heart failure: a double-blind randomised placebo controlled trial. Eur Heart Journal 27, 57-64

return to view all presentations

Copyright © 2006 ISSAM
Intellectual property rights remain with the authors.